REG - IXICO plc - Contract Win

IXICOAnnouncement

19/06/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240619:nRSS9337Sa&default-theme=true

RNS Number : 9337S  IXICO plc  19 June 2024

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the UK version of the EU
Market Abuse Regulation 596/2014 which is part of UK law by virtue of the
European Union (Withdrawal) Act 2018, as amended and supplemented from time to
time. Upon the publication of this announcement, this inside information is
now considered to be in the public domain.

 

 

19 June 2024

IXICO plc

("IXICO" or the "Company")

 

New pharma client contract win valued in excess of £1m for a study of a
Parkinsonian disorder

 

IXICO plc (AIM: IXI), the precision analytics company delivering intelligent
insights in neuroscience, is pleased to announce that it has been contracted
by a top five CRO on behalf of a new pharma client to provide its imaging
biomarker services for a Phase 3 clinical trial for patients with a type of
Parkinsonian disorder. The trial is due to run for just under 5 years and is
worth in excess of £1m.

 

Giulio Cerroni, Chief Executive Officer of IXICO, commented:

"Following the new contract win announced on 23(rd) May in Alzheimer's
Disease, we are delighted to be announcing the award of a contract from a new
client to support the development of a promising treatment targeting a
Parkinsonian disorder. We are pleased that our expertise in providing imaging
analysis and radiological reads across clinical trials for a broadening range
of neurodegenerative disorders, is increasingly recognised across the drug
development industry and continues to attract new Sponsors seeking these
expert services."

 

 

For further information please contact:

 

 IXICO plc                                                                         +44 (0) 20 3763 7499
 Giulio Cerroni, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser and                          +44 (0) 20 7220 0500

 Sole Broker)
 Giles Balleny / Dan Hodkinson (Corporate Finance)

 Nigel Birks/Harriet Ward (Corporate Broking)

 Michael F Johnson / Tamar Cranford Smith (Sales)

 

 

 

About IXICO

 

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's disease, Parkinson's disease and Alzheimer's disease. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough data analytics, at scale,
through its remote access technology platform, to improve the return on
investment in drug development and reduce risk and uncertainty in clinical
trials for the Company's pharmaceutical clients.

 

More information is available on www.IXICO.com (http://www.ixico.com/)  and
follow us on Twitter @IXICOnews

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTUWOVRSVUNAAR